Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001193125-25-272748·BCLS II Investco, LP
Schedule 13D ownership disclosure
NEWAMSTERDAM PHARMA COMPANY
Ordinary Shares, nominal value Euro 0.12 per share · CUSIP: N62509109
Event date: 2025-11-05
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BCLS Fund III Investments, LPReported CIK 0001952107
Shares: 11,422,504 · Class: 9.99%
- Bain Capital Life Sciences Opportunities III, LPReported CIK 0001950105
Shares: 11,422,504 · Class: 9.99%
- Bain Capital Life Sciences Fund II, L.P.Reported CIK 0001773187
Shares: 11,422,504 · Class: 9.99%
- BCLS II Investco, LPReported CIK 0001818893
Shares: 11,422,504 · Class: 9.99%
- BCLS II Equity Opportunities, LPReported CIK 0001814474
Shares: 11,422,504 · Class: 9.99%
- BCIP Life Sciences Associates, LPReported CIK 0001702921
Shares: 11,422,504 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-272748
- Form type
- SCHEDULE 13D/A
- Filer
- BCLS II Investco, LP
- CIK
- CIK 1818893
- Filed
- Nov 07, 2025
- Reporting period
- Nov 05, 2025
- Description
- Schedule 13D beneficial ownership